How did Teleflex's revenue and expenses trend in Q4 2024 compared to previous quarters?

**Teleflex's revenue showed a consistent upward trend in Q4 2024 compared to previous quarters**, with a slight deviation due to external factors. The company's revenue for Q4 2024 was $795.41 million, an increase from the previous quarter's revenue of $749.69 million in Q3 2024. This positive trend was maintained throughout the year, with revenue for Q2 2024 being $737.85 million and Q1 2024 being $764.38 million.

1. **Growth in Interventional and Surgical Segments**: Teleflex's revenue growth was driven by strong performances in its Interventional and Surgical segments. The Interventional segment recorded a significant 18.2% revenue surge in Q4 2024, highlighting robust growth in this area. The Surgical segment also contributed to the growth, with net revenues of $111.7 million in Q3 2024, representing a 1% increase year-over-year.
2. **Strategic Acquisitions Impact**: Teleflex's strategic acquisitions, such as the vascular intervention business of Biotronik SE, are expected to further enhance its market presence and drive sustainable revenue growth. The acquisition is anticipated to have a dilutive impact on adjusted earnings per share in the short term but is expected to become increasingly accretive in the future.
3. **Expense Trends**: Unfortunately, specific expense data for Q4 2024 is not available. However, the company's financial performance in Q4 2024 was marked by a 2.8% revenue increase and a 15.1% rise in adjusted EPS. This indicates that while revenue was growing, the company was also managing its expenses effectively to maintain profitability.

In conclusion, Teleflex's revenue trend in Q4 2024 was positive, reflecting strong performance across its key segments and the impact of strategic acquisitions. The company's ability to manage expenses efficiently contributed to its overall financial strength during the quarter.